Thus, TRIB2 emerges as a new driver (rather than just a biomarker) that helps prostate cancer cells to evade enzalutamide therapy, apparently by switching their identity from the parental luminal type and developing NE characteristics. This evidence concerns the gene TRIB2 and Familial prostate cancer.